SHANGHAI, Jan. 22, 2013 /PRNewswire/ -- The "hot cake" of the China medical devices market has attracted close eyes from EU/US companies. With a perfect blend of local and international market intelligence, Dr. Daozhi Liu from MicroPort will share details about the future of biomedical materials in the Chinese market this March at BioMed China 2013.
China's Twelfth "Five-Year Plan" has announced that, until 2015, biomedical materials such as bio-ceramics and medical metals will increase significantly in China. Regarding biomedical materials projects, the Plan clearly points out that the State will vigorously develop medical metals and alloys such as medical polymer materials, bio-ceramics, and other related products to meet the demand for artificial organs, vascular stents and implants. This will promote the field of materials technologies, life sciences and clinical trials, as well as reduce R&D risks and production costs.
Dr. Daozhi Liu is currently Senior Vice President of Emerging Business at Shanghai MicroPort Medical (Group) Limited. He obtained his bachelor's and Ph.D. in China in 1985 and 1991, as well as engaged in postdoctoral research at the University of Oxford from 1993 to 1994. He returned from overseas to join MicroPort Medical (Shanghai) Co., Ltd. as one of the core members of the early entrepreneurial team, former research center director, vice president, senior vice president, business general manager, Ortho business company legal representative and executive director. From 2003 until now, he established MicroPort's emerging business of cardiac electrophysiological medical equipment: pacemakers and orthopedic medical devices. He is
|SOURCE UBM China|
Copyright©2012 PR Newswire.
All rights reserved